AC Immune SA's stock surged by 40.14%, reaching a 20-day high, amid a generally weak market with the Nasdaq-100 down 0.45% and the S&P 500 down 0.29%.
This increase is attributed to the successful Phase 2 VacSYn trial results for ACI-7104.056, which demonstrated significant slowing of Parkinson's disease progression, marking a breakthrough in treatment options. The therapy showed a 100% responder rate in a cohort of 34 patients, with no clinically relevant safety issues reported, indicating a strong safety profile and potential for further development.
The implications of these results are substantial, as AC Immune plans to engage with regulators to discuss a clinical development plan for ACI-7104.056, aiming to accelerate the registration process. This positive news could enhance investor confidence and drive future growth for the company.
Wall Street analysts forecast ACIU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACIU is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast ACIU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACIU is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.400
Low
12.00
Averages
12.00
High
12.00
Current: 3.400
Low
12.00
Averages
12.00
High
12.00
HC Wainwright & Co.
Andrew Fein
Strong Buy
Reiterates
$16
2025-04-03
Reason
HC Wainwright & Co.
Andrew Fein
Price Target
$16
AI Analysis
2025-04-03
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Andrew Fein
Strong Buy
Reiterates
$16
2025-03-14
Reason
HC Wainwright & Co.
Andrew Fein
Price Target
$16
2025-03-14
Reiterates
Strong Buy
Reason
About ACIU
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
